Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Sanofi to EUR 114 from EUR 120 and keeps a Buy rating on the shares as the firm updated its model post-Q4 and to account for prescription trends. The firm expects Dupixent’s June 27 PDUFA action date in COPD to be “a meaningful opportunity for the franchise,” the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Inhibrx downgraded to Hold from Buy at Jefferies
- Sanofi reports ‘positive’ results from Phase 2 RILECSU study
- Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA
- Sanofi’s RSV shot had a bumpy rollout, more popular than expected, WSJ says
- Sanofi consumer health unit seeing intertest ahead of split, Bloomberg says
